{"name":"BHV Pharma","slug":"bhv-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Biphasic Remogliflozin Etabonate","genericName":"Biphasic Remogliflozin Etabonate","slug":"biphasic-remogliflozin-etabonate","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"Biphasic Remogliflozin Etabonate","genericName":"Biphasic Remogliflozin Etabonate","slug":"biphasic-remogliflozin-etabonate","phase":"phase_2","mechanism":"Biphasic Remogliflozin Etabonate is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQZENVMU9pV1N2Z0UyR2hUSDlmd3JEclV4eUhfZTM3MFVRcjR2NmdxdUwxdXRhdmQzNFlsLXlBX0ZPc1c4RUdpdWs2Y21mM3NISU5waEx1c0V2NS16UG5yUXNEN0trUkhwdjNYdnNXV1JVVlFfMkY0djdGQXN1bnpBTHhaMjdQTHAwSFBSVDBOWjdBMGFlOWRCbVpxR29rYzR4V0FEX3R5eWtnek4tbFl6Nk9sVWhHS240dm9qaWFwbjVfRVZPWUE?oc=5","date":"2026-03-03","type":"deal","source":"Investing.com","summary":"Leerink Partners reiterates Biohaven Pharma stock Outperform rating - Investing.com","headline":"Leerink Partners reiterates Biohaven Pharma stock Outperform rating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNOGFIajZVTzJSR3pxT3dpRVc0NE81RVI3SEZSazh4NWUxOVVvbkNsTXhtTW0zQ25rUWNXclRqLWdfNFFtdGRzSjQ4R3oyd0tSaTNxdXBKcjZuRzVMUk5rYk5iMUdxZDE0NGp0ZWZVY0ppRE8td1hBeHhiaTFQMEZ4a1p4aVRFdGxaNTA0RXNEd3o3UTJOeEtVN1JVVS15YkNVSm8yVnM4UGprcnNNMzB4dndoeWRxOTlxM2hzeGh0TnUzc01kUnpKTHNDdDJYUQ?oc=5","date":"2026-02-06","type":"deal","source":"Investing.com","summary":"Goldman Sachs initiates coverage on Biohaven Pharma stock with Buy rating - Investing.com","headline":"Goldman Sachs initiates coverage on Biohaven Pharma stock with Buy rating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNTUZHUHc3cWFvOGxHZm1pMmxORkppbjJkYlVrQy1iR0ZqS2pRYTV5SW9xaUluNG1kOUtnOEtNZXVwb2RPeURNRjVocnl4aG5mTUZndDJaT19ZVk00elE1TUsyWUl6cElMSldOOTZyMXc4bzltSGVmQmQ0MFZ5dXI1WFQzQUtjTFFyQmYwRFVuUmVHZ180am5WbXFaY0NVZThzbWFQM3VCeWFJa2E3TUhj?oc=5","date":"2026-01-02","type":"trial","source":"Fierce Biotech","summary":"Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout - Fierce Biotech","headline":"Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9maFVsTndIVl8tTVc3Q3RBUjJXemlPRkZrZmh5cjA5YmhPWFljbENXUld3bl9ZTlZjLS1uM2J5ZWdqZHB6SFUtYWVjU01jMXdFLTNj?oc=5","date":"2025-12-26","type":"pipeline","source":"FirstWord Pharma","summary":"Biohaven's neuropsychiatric hopeful hits another wall - FirstWord Pharma","headline":"Biohaven's neuropsychiatric hopeful hits another wall","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNa29CNmRBYzRXQ25KMlJVY0dBajgwQ2hQNGhGNDAzSnJYcldjRlBycGFUdm9YZkRVV004b3lXLTBoaFZaOVNVdlBuNUJjRk5OS0dVVHptSXJEYjlwMU40UnVrZU5sRndjRzhoNTZmZkR6MUhOR2pMeHhyWXBIMFZTWU1rVHd6OWlPRXdXYUdFdHNJTDFmMEtoOUgySVFVVTh0MTd2VkhWWE4wVDgtSUE?oc=5","date":"2025-08-20","type":"deal","source":"MedCity News","summary":"Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug - MedCity News","headline":"Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1yd0RhNDFQQXd1ejg0XzUxcl9iU2VPamFsSG02MmVvSDFQTlc3LVRMY3BBV2ZSVlhUQ3NxTVdUUVpGUGtOY19HRTVIZ3FBUEJRcUk0?oc=5","date":"2025-03-03","type":"trial","source":"FirstWord Pharma","summary":"Biohaven skids after BHV-7000 bipolar study failure - FirstWord Pharma","headline":"Biohaven skids after BHV-7000 bipolar study failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxNTVZ3X2s2YjFmMEU5ZjRkSGZjbDZ0d1Y3NHM3bWpxZDIyc0xmMng0SlVrR21fOHlZd2RtdDY4N0UzUkdDem9vRnhZWU1lTmJQVktGaGlLLTVIeWVQd0lvaTVZYTJ1RFZveUlGMHVzQ0V2MUp5ZGl3d1Z1WXBDTE9KY3JQekltWnVUNzRod1g3R0ZYU2psTmhFVWFDNXk5TzVielRNNlBoZkljTkNwcVdJOF9BcDV6QVp5bElyM1VxM0thVi1XeDg5TEpSaFlmS09ieUxwaEFBU1FHWGFiSzJBY0ZJX1RHVGFLUmppUFk2VjhuQVVWMXFQLUFsUHZTYXVMejI4VW1oS2pXbUVvM0dSRDEyTVdUbDNSNzJWYU03TmVmaFNkR1RVcC1jZ2ZDQzhnb2NV?oc=5","date":"2025-03-03","type":"trial","source":"StreetInsider","summary":"Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - StreetInsider","headline":"Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential F","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNbWl5blh6WjBDakVZbnMwbVh5azRndEFZMjNGSGR1UG1JV1ZVYVJjUWR6M3hLdkRIYmtUOEQ5SFkwUkJXTmMydFpic2xyLTd6d2RkRUhjQVp0cDE2TWdRQkctM1d1SDZ4dWc5ZEdlX3NjekYwZm1rSUFoNC11cDFaMk1ER3ZvdUx5TG9KR1IzSjJGYnZZZFVLZDVxWmtIakVZblZ2ai05cWJPb2E0T2xCWHcwcEducGRJOUtBWkNrMXM4Wjg3a2dKWWtzRkg1Q3NKSzJlbFBoZU4yaXpQRGw2eGM1WU45em8wVVdYN0NYdm03V0FIX1V1MUxQMldGdkxKdWE5UERxNFJGWFdmWS1yT05oVUdLN0t0c1REeF9CMGlBenY5U1hUUDNQMmVCWlE?oc=5","date":"2024-04-15","type":"trial","source":"StreetInsider","summary":"Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300 - StreetInsider","headline":"Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5GRERmVnlGTW1TWTQ2SGF6bDVSS0FFUk1LWXB6R3hiTTEyWU5OdGRwOUhRUVNqVkNfeDFvaU44LVBJU3dsQjhFa0dNTmM4ZS1mT1huTFFxZU42UDNwc25ic1BpMGhwT1QwS1JpT25qVWJralZxTjRMX255b2lVb2M?oc=5","date":"2023-03-23","type":"deal","source":"Pharmaceutical Technology","summary":"Biohaven licenses Hangzhou Highlightll’s BHV-8000 to treat brain disorders - Pharmaceutical Technology","headline":"Biohaven licenses Hangzhou Highlightll’s BHV-8000 to treat brain disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPLVVyTEZteEh0c0FLcC1GZzkwVHJySWIwYk8zZVVlZmhmOTEzRFVqV1N4c1ZyQW1WOElTcjdjWmtOVFMyaHpQeWctUTFDd1lEWVJsNFFMc2xOdi1EOGRrTzlYOG9rVTFiWDdIeXNYbGk4cks1UllrdzZuQy1KTExxVGdzTG5OcDVYdWM3eWNSNFNiRG1IYmJsazNwUE9BTnF6ei1yZ2NHSlZpdFdaeTlTZHI3alFvVXk1N1N1Uw?oc=5","date":"2019-07-22","type":"regulatory","source":"NeurologyLive","summary":"FDA Cites Active Ingredient Issue With Riluzole For Treatment of Amyotrophic Lateral Sclerosis - NeurologyLive","headline":"FDA Cites Active Ingredient Issue With Riluzole For Treatment of Amyotrophic Lateral Sclerosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPWVF1eUNNNUxyN2xyOEE1T2c1c0JwVUozRm9BLS10MkRvOWJCTmdGVlJzMHhISEsxRlloZ3cwSTktV0x0dV9BUkh0R3V4SGp5c1FyZEJVMkFMa1lUM2tPMkE0ZC1UU1R5ejNDcTdVdTdkYVRGRFZVMHFvQkxkSV81QlpUenZOY0pkSDJHcHZkWkhFUkdPbDNpV0hIcHY3SzBKU2N4Smx3Rm0wQ1RyNXY3RDc0VFdPRHNNcGJEdTlmS0F5c3d0S1B4UXJDQk5xTXZfaXFtb0xGTHVKQnBiN0hfbFMwcms0ck9tX0JJNWM1M21YZkhWZlhiUWNGZzJkVVl6cWNfaFg4NXlLajBBV2FrcnlDVmlfZW15NXl1NEVLbw?oc=5","date":"2019-04-01","type":"trial","source":"prnewswire.com","summary":"Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine - prnewswire.com","headline":"Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQU0tHX0N4YTFPdk5fcjNiSlRZVzloZUVGMGZfMjd0dy0zLWY4ZnJfOEdocjRFdUM4a3hWZXR6OVZqNGZOYkljT0pFMTBhTXNQRUowZzd0bFNmai01aGhzc1JEZGFxTnROV1IxNG5Xd0ZMMVE0emRheU9oU1FYNUdUcHVBcjRIdnpBalM0WFVFTnAtMko4Yk81WF9fTkc3b2R2RUVMcDBLN2c3OURwUk5kZkJiYkw4VUJlc0U3ZmdxUktNejk1a0Rwa2RpRHFXUWdrT0doLWxfT2xPa053eHVHZTZwNFppTmItTXc3NEpzNHA?oc=5","date":"2018-06-18","type":"pipeline","source":"prnewswire.com","summary":"Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million - prnewswire.com","headline":"Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}